Program
BTK Degrader ABBV-101
Its studies are mostly in Hematologic Neoplasms, led by AbbVie.
Furthest: phase 1, since Feb 22, 20232 company-led studies, 1 open or runningNext primary completion: Mar 2031 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 21 open or running | phase 1since Feb 22, 2023 | Feb 22, 2023 | Mar 2031phase 1 · NCT05753501 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 22, 2023First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT05753501 · 135 enrolled · United States, Canada, France and more
- Mar 14, 2025Phase 1 study in Healthy VolunteerNCT06887010 · 17 enrolled · United States
Ahead
- Mar 2031Primary completion: phase 1 study in Hematologic NeoplasmsNCT05753501
TargetBeta
BTK →read by rule
“An orally bioavailable, targeted degrader of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) comprised of an E3 ubiquitin ligase binding moiety ”NCIt, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06887010Healthy Volunteer · United States | 1 | Completed | Sep 16, 2025 | 17 |
| NCT05753501Hematologic Neoplasms · United States, Canada, France and more | 1 | Active, not recruiting | Mar 2031 | 135 |
How it is read
Names in the registry
- “ABBV-101”, 2 entries
Conditions, from the studies’ own filings
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.